Acute Repetitive Seizures Market Size, Share & Trends Analysis Report By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region (U.S., U.K., Canada, Germany), And Segment Forecasts, 2018 - 2025

Industry Insights

The global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period. High unmet clinical needs for patients, as well as caregivers, and availability of advanced product pipeline are some of the major factors expected to propel market growth. Drug therapy is effective for most of the patients suffering from cluster seizures. However, there are a significant number of treatment challenges and unmet medical needs including drug-induced seizures, adverse reactions, and lack of antiepileptogenic agents that can prevent the development of seizures and its comorbidities.

In an attempt to curb healthcare expenditure, governments across the globe are making continuous efforts to reduce hospital stays and on-site patient treatment costs through outpatient care models, such as clinic and home healthcare. Emerging economies like India and China are increasingly implementing these healthcare reforms. This factor is expected to propel the growth of acute repetitive seizures market.

The treatment gap is a useful measure to compare access to quality care for patients suffering from seizures. The treatment gap for low- and middle-income countries, such as India, South Africa, and Brazil, is around 80%, while it is around 60% in developed countries, such as U.S. and U.K.

Among the many routes of medicine administration, patients prefer the intranasal route over other types, such as buccal, rectal, and intramuscular route. Parenteral medications have proven to be the optimal option for outpatient treatment. However, in some countries, such as the Netherlands, caregivers are not qualified for administrating parenteral medications.

Product Insights

Based on product, the market is categorized into USL-261, NRL-1, AZ-002, Diastat Rectal Gel {DRG}, and others. Diastat Rectal Gel led the product segment in 2017 owing to its efficiency and lack of FDA-approved drugs in the market. It is the only FDA-approved drug and the generic versions of it were introduced in 2010.

NRL-1 is expected to be the fastest-growing segment over the forecast period. It is an investigational drug developed by Neurelis to be used for children, adolescents, and adults. The company filed NDA with the FDA in September 2018. USL-261 is expected to show lucrative growth over the forecast years and is specifically designed for intranasal administration for outpatient use.

Regional Insights

The U.S. held a share of 17.0% in 2017 in the global market. According to the data published by the CDC, around 4.3 million adults and 750,000 children in the U.S. had epilepsy in 2014. Also, the total direct and indirect cost of epilepsy in this region is estimated to be around USD 15.5 billion annually. Thus, the presence of a large target population base for epilepsy drugs in this region will spur the market growth.

Germany is expected to witness robust growth over the forecast period owing to technological advancements in scientific, clinical, and medical fields. Increasing demand for antiepileptic drugs due to rising disease prevalence in the region fosters market growth. Government initiatives, in an attempt to improve the quality of life and awareness regarding the disease, coupled with the promotion of better healthcare facilities are the major drivers boosting the market growth in this region.

The Asia Pacific market is also likely to witness rapid development on account of increasing healthcare expenditure in developing countries, such as India and China. A huge gap was observed in the treatment for acute repetitive seizures in this region. Hence, the demand for the antiseizure drugs in these developing countries encourages a shift in market potential from the already saturated European and North American regions to such economies.

Acute Repetitive Seizures Market Share Insights

UCB S.A. and Neurelis, Inc. are likely to hold the major share of the global market due to the commercialization of USL-261 and VALTOCO. As both the drugs (USL-261 and VALTOCO) are granted orphan drug designation, the prices will be usually high. In addition, as per our studies, the preferred route of administration is nasal, which in turn will result in higher adoption of these two drugs.

Report Scope

Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2013 to 2025. For the purpose of this study, Grand View Research has segmented the global acute repetitive seizures market report on the basis of product and region:

• Product Outlook (Revenue, USD Million, 2013 - 2025)

  • USL-261

  • NRL-1

  • AZ-002

  • Diastat Rectal Gel

  • Others

• Regional Outlook (Revenue, USD Million, 2013 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

  • Rest of World